Landmark Trials
at Boehringer Ingelheim

Uncovering Answers to Protect Patients' Health

As an innovative, research-driven pharmaceutical company Boehringer Ingelheim conducts and sponsors clinical trials to establish the safety and efficacy of the drugs we develop, either for use in their initial indication or in additional indications. In 2008, Boehringer Ingelheim presents results from large-scale, randomised, controlled landmark trials in cardiovascular, respiratory and cerebrovascular diseases. These landmark trials are running in more than 40 countries and involve more than 70,000 patients.

About Clinical Trials

Boehringer Ingelheim conducts and sponsors clinical trials to establish safety and efficacy of the drugs we develop, either for use in their initial indication or in additional indications. read more

Boehringer Ingelheim Landmark Trials
  • ONTARGETONTARGET®
    This groundbreaking study programme explores therapeutic options in cardiovascular protection.
    read more
  • PRoFESSPRoFESS®
    The largest ever trial exploring therapeutic options in prevention of secondary stroke.
    read more
  • UPLIFTUPLIFT®
    UPLIFT® (Understanding Potential Long-term impacts on Function with Tiotropium) is a four-year landmark trial involving nearly 6.000 patients with COPD.
    read more
  • RE-LYRE-LY™
    This trial evaluates the long-term anticoagulant therapy with dabigatran etexilate.
    read more